Logo-npj
Submitted: 02 Apr 2020
Accepted: 07 May 2020
ePublished: 27 May 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2021;10(1): e02.
doi: 10.34172/npj.2021.02
  Abstract View: 372
  PDF Download: 137

Mini-Review

The impact of metformin in chronic kidney disease-mineral and bone disorder

Rohollah Masumi 1, Ramin Tolouian 2 ORCID logo, Audrey Tolouian 3 ORCID logo, Leila Mohmoodnia 1 * ORCID logo

1 Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 Division of Nephrology, University of Arizona, Tucson, AZ, USA
3 School of Nursing, University of Texas, El Paso, TX, USA
*Corresponding author: Leila Mohmoodnia, Email: leilamahmoodnia@yahoo.com

Abstract

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a disorder of mineral and bone metabolism due to chronic kidney disease (CKD). Bone disease and mortality are more common in patients with CKD. In addition of antidiabetic properties of metformin (MET), it possesses anti-inflammatory, anti-fibrotic properties and increases the markers of osteogenic effects. Therefore, it improves bone quality and decreases the risk of fractures in patients with type 2 diabetes. Metformin can also inhibit arterial calcification, maintain calcium-phosphorus balance, decrease cellular infiltration, fibrosis, and inflammation in kidney. Based on evidence, the prevalence of lactic acidosis due to metformin in patients with type 2 diabetes (T2D) and renal dysfunction is lower compared to other oral antidiabetic agents. Metformin decreases all-cause mortality in patients with diabetic nephropathy. The administration of metformin showed no difference in the prevalence of lactic acidosis in patients with T2D who had normal, mild, moderate, or severe renal dysfunction. Therefore, metformin can be used in patients with significant CKD to inhibit CKD-MBD due to its osteogenic effects.
Keywords: Metformin, Chronic kidney disease-mineral and bone disorder, Bone fracture

Implication for health policy/practice/research/medical education:

Metformin can be used in patients with significant chronic kidney disease, while inhibiting CKD-MBD (chronic kidney disease-mineral and bone disorder) due to its osteogenic effects.

Please cite this paper as: Masumi R, Tolouian R, Tolouian A, Mohmoodnia L. The impact of metformin in chronic kidney disease-mineral and bone disorder. J Nephropharmacol. 2021;10(1):e02. DOI: 10.34172/npj.2021.02.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 372

Your browser does not support the canvas element.


PDF Download: 137

Your browser does not support the canvas element.